RLYB
Rallybio Corporation Common StockstockNASDAQ
rallybio is a privately-held early-stage biotechnology company incorporated in january 2018. our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. we will work on highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. rallybio's founders are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. the company is based in farmington, ct, at the university of connecticut's technology incubation program. we are assembling a small team of people with an outstanding track record in pharmaceutical research and development to search for and evaluate assets using a series of robust clinical and commercial filters tha
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 15.65 | 2026-11-12 | -2.49% | 1.267 |
| 1M | 16.35 | 2026-10-19 | -6.67% | 0.075 |
| 3M | 17.00 | 2026-08-19 | -10.23% | 0.120 |
| 6M | 14.19 | 2026-05-19 | +7.54% | 0.220 |
| 1Y | 4.99 | 2025-11-19 | +205.59% | 0.534 |
| 2Y | 7.68 | 2024-11-19 | +98.61% | — |
| 5Y | 108.40 | 2021-11-19 | -85.92% | 1.080 |
Rallybio Corporation Common Stock (NASDAQ:RLYB) stock price today is $15.26, and today's volume is 28,937. RLYB is down 0.196% today. The 30 day average volume is 30,308. RLYB market cap is $85.46M with 5.60M shares outstanding.